Maria Carvalho discusses the latest versions of the USP (43rd edition) and NF (38th edition), as well as the corresponding USP Compounding Compendium, recognizing the importance of several proprietary PCCA bases

Nat Jones, one of PCCA's Clinical Compounding Pharmacist, discusses the importance of naltrexone and how compounders can use Low-Dose Naltrexone therapy, especially with dermatological health challenges.

Maria Carvalho, Manager of PCCA Science, provides an in-depth look at the science behind Ellage, the first ever anhydrous compounding base developed specifically for vaginal delivery of medications.

Maria Carvalho briefly discusses and provides 8 of the published, peer-reviewed stability studies of compounded medications with PCCA's SuspendIt. These studies were conducted by the researchers at Xavier University of Louisiana.

Members of PCCA's Clinical Services and PCCA Science teams provide a review of some of the research into the morbidity, mortality and pathogenicity of SARS-CoV-2. The information gathered is based on the best scientific evidence currently available regarding potential treatments. They also take the time to explore some potential non-prescription and prescription options based on their research.

Maria Carvalho, PharmD, MRPharmS, PhD, Manager of PCCA Science, provides an exciting update regarding treatment of oral lichen planus, a formulation study for surgical wound healing and a whole lot more in this PCCA Science Update!

Nat Jones of PCCA's Clinical Services Team discusses the clinical data about the efficacy of Permeation-enhanced topical pain therapy (PETPT) or transdermal pain therapy. He provides a brief history of transdermal pain therapy and evidence of the levels of efficacy PETPT has within medicine.

As long as COVID-19 is spreading in communities, everyone is encouraged to practice social distancing and face-covering, regular and thorough hand hygiene, appropriate respiratory hygiene, and good disinfection habits. PCCA Science has been researching published literature and would like to discuss what evidence is currently available regarding the questions revolving around hygiene, social distancing, and good disinfection habits.

Yi Liu, PCCA Research Pharmacist, provides an exciting update regarding new therapies, the extension of beyond-use dates (BUDs) for compounding formulations, evaluating compounding equipment and a whole lot more in this PCCA Science Update!

In the first part of this article, Pamela, Nat, and Sara shined a light on new health risk information compounders should consider when providing bioidentical hormone replacement therapy. In this second part of the article, they dive deeper into the BHRT conversation, discussing compounded topical estrogen as an option.